In particular, chest discomfort, edema, and dyspnea are common among patients on HER2 blockers and/or anthracycline-based medications, though it is worth noting that the development of those HF-related symptoms manifested later than patients who were on capecitabine (Kim et al., 2024). Here, ERBB2 is linked to hydrops fetalis.